08:59 AM EST, 01/14/2025 (MT Newswires) -- Adaptive Biotechnologies ( ADPT ) and NeoGenomics ( NEO ) said Tuesday they are partnering to support access to minimal residual disease monitoring options for patients with certain blood cancers.

The multiyear deal is meant to support bespoke treatment strategies and immediate insights into disease progression, the companies said.